Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Study Identifier
1698-301-007
CT.gov Identifier
EudraCT Identifier
EUCTIS ID
2022-502380-37-00
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
  • Study Drug
  • Bimatoprost (SR)
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.

    Study Locations

    Location
    Status
    Location
    Horizon Eye Specialists & Lasik Centers /ID# 235240
    Sun City, Arizona, United States, 85351
    Status
    Not applicable
    Location
    Atlantis Eye Care /ID# 235530
    Huntington Beach, California, United States, 92647
    Status
    Not applicable
    Location
    Lakeside Vision Center /ID# 234970
    Irvine, California, United States, 92604
    Status
    Not applicable
    Location
    Global Research Foundation /ID# 237350
    Los Angeles, California, United States, 90041-1718
    Status
    Not applicable
    Location
    The Eye Research Foundation /ID# 234521
    Newport Beach, California, United States, 92663-3637
    Status
    Not applicable
    Location
    Byers Eye Institute Stanford /ID# 235544
    Palo Alto, California, United States, 94303
    Status
    Not applicable
    Showing {first} - {last} of {total} Results